| 货号 | HC496026 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Chimeric |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | CAK1 antigen, Mesothelin, MSLN, Pre-pro-megakaryocyte-potentiating factor, MPF |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | Q13421 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | MORAb-009, 931402-35-6 |
| 背景 | Amatuximab, alternative names: MORAb-009, anti-MSLN monoclonal antibody (MAb) is a chimeric, humanized IgG1/k MAb that targets the cell surface Mesothelin (MSLN). The precursor of MORAb-009 was isolated by Chowdhury et al in 1998 56 from a mouse splenic mRNA and was then optimized by fusing the gene encoding MSLN Fv (SS1 scFv) with human IgG1 and kappa regions. It was first designed to treat patients with mesothelin-positive cancers (pancreatic, ovarian, mesothelioma and lung). Amatuximab is not yet commercially available, and the highest development phase is Phase II. In addition, on 16 January 2014, orphan designation (EU/3/13/1222) was granted by the European Commission to Eisai Europe Limited, United Kingdom, for amatuximab for the treatment of malignant mesothelioma. • Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum., PMID:24167356 • Exon deletion in the MSLN gene encoding MPF/mesothelin precursor protein during Laurasiatherian mammal evolution., PMID:21132261 • Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma., PMID:31267149 • Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers., PMID:22149739 • Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin., PMID:18394747 • Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma., PMID:20075387 • Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma., PMID:10500211 • Asbestos-related disease: screening and diagnosis., PMID:22870590 • Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice., PMID:25118887 • Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine., PMID:34876673 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Amatuximab.
Detects MSLN in indirect ELISAs.
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
